These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 38388872

  • 1. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M.
    Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
    Kanu JE, Soldera J.
    World J Gastroenterol; 2024 Mar 07; 30(9):1213-1223. PubMed ID: 38577188
    [Abstract] [Full Text] [Related]

  • 3. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection.
    Liu L, Nahata MC.
    Ann Pharmacother; 2023 Oct 07; 57(10):1185-1197. PubMed ID: 36688309
    [Abstract] [Full Text] [Related]

  • 4. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW.
    Gastroenterology; 2022 Sep 07; 163(3):608-619. PubMed ID: 35679950
    [Abstract] [Full Text] [Related]

  • 5. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
    Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY.
    Dig Dis Sci; 2016 Nov 07; 61(11):3215-3220. PubMed ID: 27659671
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.
    Gut; 2016 Sep 07; 65(9):1439-46. PubMed ID: 26935876
    [Abstract] [Full Text] [Related]

  • 10. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL.
    Aliment Pharmacol Ther; 2022 Aug 07; 56(3):436-449. PubMed ID: 35665947
    [Abstract] [Full Text] [Related]

  • 11. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.
    Ann Clin Microbiol Antimicrob; 2018 Jun 28; 17(1):29. PubMed ID: 29950163
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
    Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y.
    Intern Med; 2019 Jun 01; 58(11):1549-1555. PubMed ID: 30713328
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
    Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H.
    Helicobacter; 2022 Oct 01; 27(5):e12918. PubMed ID: 35877765
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H.
    J Gastroenterol; 2020 Oct 01; 55(10):969-976. PubMed ID: 32666199
    [Abstract] [Full Text] [Related]

  • 19. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z, Chen X, Sun DJ, Zhao WW, Kou L, Zheng WW, Hao JR, Gao FY.
    Medicine (Baltimore); 2024 Mar 08; 103(10):e37476. PubMed ID: 38457567
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.